BioSpace News Archive

HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors

Hemingway Hall delivers care management and financial leadership expertise to the MSU Foundation and MSU community

VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules. VBL has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggr

50 hospitals to date add tele-ICU clinical and operational capacity to address patient surge [07-May-2020] ST. LOUIS , May 7, 2020 /PRNewswire/ -- In response to the urgent need for the treatment of COVID-19 patients amid the current pandemic, Advanced ICU Care , the nation’s leading provider of high-acuity telemedicine, announced accelerated tele-ICU care launches a

Los Angeles-area biomedical research institute participates in 2000-person trial for potential coronavirus treatment

Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL (link available here ) . Principal investigators Dr. Ronald T

Oculis S.A. announces that a presentation of results from its Phase 2 clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, will be made at the American Society of Cataract and Refractive Surgery Annual Meeting, which will be held online on May 16-17, 2020.

Agenus Inc., an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and reported financial results for the first quarter of 2020.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

C Integrated, surgeons now have a zero profile, screw fixated interbody option for anterior cervical fusions with all the benefits of the SPIRA®- open architecture design.